Maynard Um
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Editas Medicine (EDIT) following Q4 results
-
-
-
-
-
-
-
Editas Medicine to present EDIT-401 data at gene therapy congress
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) gains on continued chatter
-
-
-
-
-
-
-
Editas Medicine (EDIT) Misses Q4 EPS by 22c
-
-
-
-
-
-
-
Editas Medicine (EDIT) PT Lowered to $8 at Baird
-
-
-
-
-
-
-
Evercore ISI Upgrades Editas Medicine (EDIT) to Outperform
-
-
-
-
-
-
-
Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo
-
432,019 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

